Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 6498–6500.

https://doi.org/10.1182/blood-2022-163683

Published: 2022

Journal Articles

Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS

Justin M Watts, Tara L. Lin, Alice S. Mims, Prapti Patel, Paul J Shami, Elizabeth H. Cull, Christopher R. Cogle, Cynthia Lee, Fatih Uckun

Blood (2021) 138 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2021-149337

Published: 2021

Journal Articles

Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Tara L. Lin, Justin M Watts, Alice S. Mims, Prapti Patel, Paul J Shami, Elizabeth H. Cull, Christopher R. Cogle, Cynthia Lee, Fatih Uckun

Blood (2021) 138 (Supplement 1): 3416.

https://doi.org/10.1182/blood-2021-149366

Published: 2021

Journal Articles

CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial

Sikander Ailawadhi, Patrick Stiff, Emad Ibrahim, Damian J. Green, Brea Lipe, Elizabeth H. Cull, Natalie S. Callander, John Friend, Jarrod Longcor, Kate Oliver

Blood (2021) 138 (Supplement 1): 1652.

https://doi.org/10.1182/blood-2021-152682

Published: 2021

Journal Articles

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin M. Watts, MD, Tara Lin, MD, Eunice S. Wang, MD, Alice S. Mims, MD, Elizabeth H. Cull, MD, Prapti A. Patel, MD, Paul J. Shami, MD, Roland B. Walter, MDPhDMS, Christopher R. Cogle, Ruth A. Chenault, MS, Bret Macpherson, MSc, MBA, Allison Given Chunyk, Catherine J. McMahan, Jane A. Gross, PhD, Scott Stromatt, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141619

Published: 2020

Journal Articles

Analyzing the Efficacy and Design Considerations of VR Environments to Manage Anxiety & Depression in AYA Cancer Patients

Elizabeth H. Cull, MD, Aniket Saha, MD MS, Laura Michelle Stanley, PhD, Vishnunarayan Prabhu, MS, Joshua Biro

Blood (2019) 134 (Supplement_1): 3441.

https://doi.org/10.1182/blood-2019-128201

Published: 2019

Journal Articles

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Carmelo Carlo-Stella, MD, Pier Luigi Luigi Zinzani, MD, Brad S. Kahl, MD, Paolo F Caimi, MD, Melhem Solh, MD, William Townsend, MRCP,MDFRCPath, Anastasios Stathis, MD, Elizabeth H. Cull, MD, Mehdi Hamadani, MD, Alexander I. Spira, PhD MD FACP, Jay Feingold, MD PhD, David Ungar, MD, Shui He, PhD, Yajuan Qin, John Radford

Blood (2019) 134 (Supplement_1): 757.

https://doi.org/10.1182/blood-2019-128401

Published: 2019

Journal Articles

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Emad Ibrahim, MBBCh, MD, Anusha Vallurupalli, MBBS, Elizabeth H. Cull, MD, Damian J. Green, MD, Kate Oliver, BS, Jarrod Longcor

Blood (2019) 134 (Supplement_1): 144.

https://doi.org/10.1182/blood-2019-131014

Published: 2019

Journal Articles

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

David A Sallman, MD, Uma Borate, MD, Elizabeth H. Cull, MD, William B. Donnellan, MD, Rami S. Komrokji, MD, Ulrich G. Steidl, MD PhD, Maria M Corvez, Marie Payton, MBA, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Amit Verma, MD

Blood (2018) 132 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2018-99-118780

Published: 2018

Journal Articles

Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma

Blood (2018) 132 (Supplement 1): 2892.

https://doi.org/10.1182/blood-2018-99-117932

Published: 2018

Journal Articles

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

Blood (2017) 130 (Supplement 1): 2771.

https://doi.org/10.1182/blood.V130.Suppl_1.2771.2771

Published: 2017

Journal Articles

Temporary and Permanent Inferior Vena Cava Filters in the Oncology Population

Suneel Deepak Kamath, MD, Elizabeth H. Cull, MD, Brady L. Stein, MD, Robert Lewandowski, MD, Brandon McMahon, MD

Blood (2016) 128 (22): 1423.

https://doi.org/10.1182/blood.V128.22.1423.1423

Published: 2016

Journal Articles

Temporary Vena Cava Filters in Oncology Patients

Elizabeth H Cull, MD, Robert Lewandowski, MD, Brady L Stein, MD, Brandon McMahon, MD

Blood (2014) 124 (21): 4247.

https://doi.org/10.1182/blood.V124.21.4247.4247

Published: 2014

Journal Articles

Clinical Use Of Anti-Xa Monitoring In Malignancy-Associated Thrombosis

Brandon McMahon, MD, Sarah Yentz, MD, Oluwatoyosi A. Onwuemene, MD, Brady L. Stein, MD, Elizabeth H. Cull, MD

Blood (2013) 122 (21): 3648.

https://doi.org/10.1182/blood.V122.21.3648.3648

Published: 2013

NARROW

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS

Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Analyzing the Efficacy and Design Considerations of VR Environments to Manage Anxiety & Depression in AYA Cancer Patients

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

Temporary and Permanent Inferior Vena Cava Filters in the Oncology Population

Temporary Vena Cava Filters in Oncology Patients

Clinical Use Of Anti-Xa Monitoring In Malignancy-Associated Thrombosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only